Full View

Survival outcomes of nonsmall cell lung cancer patients treated with Afatinib who are affected by early adverse events

JM Logan, DA Brooks, A Rowland… - Journal of …, 2021 - Wiley Online Library
Introduction. Afatinib is a first‐line treatment option for patients with an advanced nonsmall
cell lung cancer (NSCLC) expressing an epidermal growth factor receptor (EGFR) activating …
被引用次数：2 相关文章
[HTML] nih.gov

[HTML][HTML] Survival Outcomes of Nonsmall Cell Lung Cancer Patients Treated with Afatinib Who Are Affected by Early Adverse Events

JM Logan, DA Brooks, A Rowland, MJ Sorich… - Journal of …, 2021 - ncbi.nlm.nih.gov
Methods The study was a pooled post hoc analysis of the randomized trials LUX-Lung 3 and
LUX-Lung 6 which evaluated afatinib versus pemetrexed-cisplatin or gemcitabine-cisplatin …

Survival Outcomes of Nonsmall Cell Lung Cancer Patients Treated with Afatinib Who Are Affected by Early Adverse Events

JM Logan, DA Brooks, A Rowland… - Journal of …, 2021 - pubmed.ncbi.nlm.nih.gov
Introduction Afatinib is a first-line treatment option for patients with an advanced nonsmall
cell lung cancer (NSCLC) expressing an epidermal growth factor receptor (EGFR) activating …

Survival Outcomes of Nonsmall Cell Lung Cancer Patients Treated with Afatinib Who Are Affected by Early Adverse Events.

JM Logan, DA Brooks, A Rowland, MJ Sorich… - Journal of …, 2021 - europepmc.org
Methods The study was a pooled post hoc analysis of the randomized trials LUX-Lung 3 and
LUX-Lung 6 which evaluated afatinib versus pemetrexed-cisplatin or gemcitabine-cisplatin …
[PDF] scienceopen.com

[PDF][PDF] Survival Outcomes of Nonsmall Cell Lung Cancer Patients Treated with Afatinib Who Are Affected by Early Adverse Events

JM Logan, DA Brooks, A Rowland, MJ Sorich… - 2021 - scienceopen.com
Introduction. Afatinib is a first-line treatment option for patients with an advanced nonsmall
cell lung cancer (NSCLC) expressing an epidermal growth factor receptor (EGFR) activating …

Survival Outcomes of Nonsmall Cell Lung Cancer Patients Treated with Afatinib Who Are Affected by Early Adverse Events.

JM Logan, DA Brooks, A Rowland, MJ Sorich… - Journal of …, 2021 - go.gale.com
Introduction. Afatinib is a first-line treatment option for patients with an advanced nonsmall
cell lung cancer (NSCLC) expressing an epidermal growth factor receptor (EGFR) activating …

Survival Outcomes of Nonsmall Cell Lung Cancer Patients Treated with Afatinib Who Are Affected by Early Adverse Events

JM Logan, DA Brooks, A Rowland… - Journal of …, 2021 - search.proquest.com
Introduction. Afatinib is a first-line treatment option for patients with an advanced nonsmall
cell lung cancer (NSCLC) expressing an epidermal growth factor receptor (EGFR) activating …

Survival Outcomes of Nonsmall Cell Lung Cancer Patients Treated with Afatinib Who Are Affected by Early Adverse Events.

JM Logan, DA Brooks, A Rowland… - Journal of …, 2021 - search.ebscohost.com
Introduction. Afatinib is a first-line treatment option for patients with an advanced nonsmall
cell lung cancer (NSCLC) expressing an epidermal growth factor receptor (EGFR) activating …

Survival Outcomes of Nonsmall Cell Lung Cancer Patients Treated with Afatinib Who Are Affected by Early Adverse Events

JM Logan, DA Brooks, A Rowland… - Journal of …, 2021 - researchnow.flinders.edu.au
Introduction. Afatinib is a first-line treatment option for patients with an advanced nonsmall
cell lung cancer (NSCLC) expressing an epidermal growth factor receptor (EGFR) activating …
[PDF] flinders.edu.au

[PDF][PDF] Survival Outcomes of Nonsmall Cell Lung Cancer Patients Treated with Afatinib Who Are Affected by Early Adverse Events

JM Logan, DA Brooks, A Rowland, MJ Sorich… - 2021 - researchnow-admin.flinders.edu.au
Introduction. Afatinib is a first-line treatment option for patients with an advanced nonsmall
cell lung cancer (NSCLC) expressing an epidermal growth factor receptor (EGFR) activating …